Audiocure
  • About Us
    • The Company
    • Management
    • Investors
    • Scientific Advisors
  • Inner Ear Disorders
    • The Ear
    • Living With Hearing Loss
    • Hearing Loss
    • Tinnitus
    • Electrode Insertion Trauma
  • Our Technology
    • AC102
    • Application
  • Clinicial Study
  • Newsroom
    • News in Brief
    • Downloads
  • Join Us
  • English
  • Deutsch
Select Page

AudioCure Pharma GmbH to present preclinical and clinical data on its lead candidate AC102 at ARO 2023 MidWinter Meeting in Orlando (FL) on February 11-15 2023

Jan 13, 2023

12th Feb: Efficacy of AC102 for the Preservation of Residual Hearing following Cochlear Implantation   Dr. Michael Nieratschker from Allgemeines Krankenhaus Medical University of Vienna, Austria will present preclinical results performed in a model of electrode...

Inner Ear Therapeutics Summit 2022: AudioCure Pharma GmbH will present latest data on lead product AC102

Jun 7, 2022

At the start of the Phase II clinical trial, AudioCure Pharma GmbH will provide their newest insights on the mode of action of lead candidate AC102 at the 2nd Summit in Boston from 20-23 June 2022. AC102 is AudioCure’s clinical Phase I tested lead candidate for...

AudioCure Pharma’s AC102 receives FDA orphan drug designation for the treatment of sudden sensorineural hearing loss (SSNHL)

Mar 23, 2021

The FDA has granted orphan drug designation to AC102, concluding that AudioCure’s lead compound may become of significant benefit for patients suffering with the rare and chronically debilitating disease of sudden sensorineural hearing loss (SSNHL). Comprehensive...

© 2017
AudioCure Pharma GmbH
Schlegelstraße 9
10115 Berlin

  • Legal Notice
  • Data Protection
  • Contact Us